RPG Life Sciences Eyes More Acquisitions To Expand API Portfolio Over Next 12 Months

Market snapshot: RPG Life Sciences is actively scouting for strategic acquisitions over the next 12 months to expand its Active Pharmaceutical Ingredients (API) portfolio and scale operations. This strategy follows its recent carve-out of its API arm into a subsidiary and the acquisition of Raghava Life Sciences' API business.

Data Snapshot

• RPG Active Pharma is acquiring the API and intermediates business of Raghava Life Sciences for up to ₹135 crore.
• Private equity firm InvAscent is investing up to ₹243 crore in RPG Active Pharma to fund the platform's expansion.
• The acquisition of Raghava Life Sciences brings a portfolio of 22 commercialised APIs and 7 development-stage assets.
• Raghava Life Sciences' API business reported approximately ₹19 crore in revenue for FY26.

What's Changed

• RPG Life Sciences completed the slump sale transfer of its API business to its wholly owned subsidiary, RPG Active Pharma, on August 15, 2026.
• The newly formed subsidiary immediately signed an agreement to acquire Raghava Life Sciences' API assets for ₹135 crore to accelerate its growth timeline.

Key Takeaways

• Strategic API Pivot: RPG Life Sciences is transforming its business model by scaling its synthetic API platform as a third growth engine alongside formulations.
• PE-Backed Growth: An investment of up to ₹243 crore from healthcare private equity firm InvAscent provides the necessary capital to fund acquisitions.
• Immediate Asset Addition: The Raghava transaction brings 22 commercialized APIs and 7 development-stage molecules, lowering time-to-market in chronic therapeutic segments.

SAHI Perspective

RPG Life Sciences is playing a clever consolidation game. Building EU-GMP compliant synthetic API manufacturing capacity organically can take years and carries significant regulatory risk. By leveraging its newly carved-out subsidiary RPG Active Pharma and PE partner InvAscent, the company is using a buy-and-build strategy to acquire ready-to-scale assets. While paying up to ₹135 crore for Raghava's assets—which generated ₹19 crore in FY26 revenue—might seem optically expensive, the value lies in acquiring a ready portfolio of 29 molecules and a highly compliant manufacturing base in Visakhapatnam.

Market Implications

The move highlights a broader sector-shift in the Indian pharma space toward de-risking supply chains and adopting integrated API-to-formulation models. Success in scaling these acquired API assets could significantly improve RPG Life Sciences' gross margins and backward integration, enhancing its competitiveness in international formulations.

Trading Signals

Market Bias: Bullish

The strategic carve-out of the API business combined with a ₹243 crore PE fund infusion and the immediate ₹135 crore acquisition of Raghava Life Sciences provides a clear pathway to scale.

Overweight: Pharmaceuticals, Active Pharmaceutical Ingredients (APIs)

Trigger Factors:

• Completion of the Raghava Life Sciences acquisition within the estimated 30-day window.
• Integration and utilization ramp-up of the acquired Visakhapatnam API facility.
• Additional USFDA-approved asset acquisitions over the next 12 months.

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian API sector is experiencing strong tailwinds as companies focus on local manufacturing and export opportunities. Strategic buyouts of established, compliant plants allow mid-sized pharma companies to bypass lengthy greenfield setup times and complex regulatory approvals, providing immediate market-ready capacity.

Key Risks to Watch

• Potential delays in aligning operations and upgrading Raghava Life Sciences' newly acquired manufacturing facilities to meet global regulatory standards.
• Acquiring relatively low-revenue assets at a premium could depress return ratios in the short term if capacity utilization is not scaled rapidly.

Recent Developments

In July 2026, RPG Life Sciences partnered with Archerchem Healthcare to launch Naprosyn ES, a chronic pain management combination, in India. On August 15, 2026, the company completed the slump sale transfer of its API business to its subsidiary RPG Active Pharma.

Closing Insight

RPG Life Sciences is systematically building a high-margin, scalable synthetic API platform. With structured private equity backing and an aggressive 12-month acquisition roadmap, the company is well-positioned to unlock significant long-term value, transforming itself from a formulation-centric player into an integrated global pharmaceutical competitor.

High Performance Trading with SAHI.